Review anchor
3-phosphoinositide-dependent protein kinase 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
3-phosphoinositide-dependent protein kinase 1
CHEMBL2534
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats 3-phosphoinositide-dependent protein kinase 1 as ChEMBL target CHEMBL2534, mapped to UniProt O15530. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2534
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O15530
3-phosphoinositide-dependent protein kinase 1
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why 3-phosphoinositide-dependent protein kinase 1 matters
3-phosphoinositide-dependent protein kinase 1 is reviewed as 3-phosphoinositide-dependent protein kinase 1 (UniProt O15530); 3-phosphoinositide-dependent protein kinase 1 shows clinical signal disease relevance led by lymphoma. 5 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 5 approved drugs, 3962 compounds, and 510 assays, with lead potency reaching pChEMBL 9.3.
Protein context
3-phosphoinositide-dependent protein kinase 1
3-phosphoinositide-dependent protein kinase 1 Sequence length is 556 aa.
Review this target as 3-phosphoinositide-dependent protein kinase 1, mapped to UniProt O15530. Sequence length is 556 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt O15530
Protein
Disease context
lymphoma
3-phosphoinositide-dependent protein kinase 1 shows clinical signal disease relevance led by lymphoma. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include AR-12, UCN-01.
Start review with lymphoma because it currently carries clinical signal support. Linked drugs include AR-12, UCN-01. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Clinical signal
2 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 5 approved drugs, 3962 compounds, and 510 assays for this target. The dominant activity type is IC50. CHEMBL388978 is the current potency anchor at pChEMBL 9.3.
Use CHEMBL388978 as the tractability anchor when discussing potency (pChEMBL 9.3).
Activity source · ChEMBL 36 via Core Engine
5 approved
pChEMBL 9.3
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why 3-phosphoinositide-dependent protein kinase 1 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt O15530, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why lymphoma is currently treated as clinical signal support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
3962
Total Compounds
510
Total Assays
5
Approved Drugs
IC50: 2235.0, KI: 725.0, EC50: 33.0, KD: 195.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL388978
|
9.3 | IC50 | — |
|
|
No preferred name
CHEMBL1940246
|
9.2 | Ki | — |
|
|
No preferred name
CHEMBL1938415
|
9.2 | Ki | — |
|
|
No preferred name
CHEMBL1765751
|
9.2 | IC50 | — |
|
|
No preferred name
CHEMBL1940251
|
9.2 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
Source Header